<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1934">
  <stage>Registered</stage>
  <submitdate>18/04/2008</submitdate>
  <approvaldate>18/04/2008</approvaldate>
  <nctid>NCT00664378</nctid>
  <trial_identification>
    <studytitle>Efficacy Study of CYT997 in Multiple Myeloma</studytitle>
    <scientifictitle>A Prospective, Single-arm, Two-stage, Open-label Phase II Trial of CYT997 in Relapsed and Refractory Multiple Myeloma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CCL07001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsed and Refractory Multiple Myeloma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CYT997

Experimental: I - CYT997


Treatment: drugs: CYT997
Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma - The overall response rate to CYT997 when used to treat patients with relapsed or refractory multiple myeloma once every 3 week cycle</outcome>
      <timepoint>Baseline to study completion</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of cycles required to achieve maximum response</outcome>
      <timepoint>Baseline to study completion</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Baseline to study completion</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability</outcome>
      <timepoint>Baseline to study completion</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to disease progression</outcome>
      <timepoint>Baseline to study completion</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of multiple myeloma per International Working Group (IWG) criteria

          -  Have received at least 1 but no more than 4 prior lines of therapy

          -  Have failed to respond to the most recently administered anti-myeloma therapy

          -  Have a life expectancy of at least 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 3

          -  At registration absolute neutrophil count &gt; 1x10^9/L and platelet count &gt; 50 x 10^9/L
             unsupported

          -  At registration bilirubin less than 1.5 x upper limit of normal and transaminases less
             than 2 x upper limit of normal and serum creatinine less than 0.19 mmol/L

          -  Written informed consent

          -  Must agree to adequate contraceptive measure if indicated</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patients with monoclonal gammopathy of undetermined significance

          -  Known or suspected hypersensitivity to CYT997

          -  Patient with uncontrolled intercurrent illness

          -  Active infections or other illnesses that precludes chemotherapy administration or
             patient compliance.

          -  Pregnant or lactating women.

          -  Patients who have received any other investigational agents in the last 3 weeks prior
             to the start of treatment.

          -  Patients with the following conditions will be excluded:

               -  myocardial infarction or stroke within 6 months

               -  unstable angina pectoris or acute ischemic changes on ECG

               -  history of diabetic retinopathy

               -  symptomatic peripheral arterial disease

               -  major surgery in the last 30 days

          -  Patients with uncontrolled diarrhea despite optimal medication and those with any
             history of acute gastrointestinal bleeding

          -  Patients with a baseline prolongation of the QTc interval of Common Terminology
             Criteria (CTC) Grade 1 (QTc &gt; 0.45-0.47 sec) or greater

          -  Patients with impaired cardiac function or clinically significant cardiac diseases,
             including any one of the following:

               -  left ventricular ejection fraction (LVEF) &lt; 45% as determined by multigated
                  acquisition (MUGA) scan or echocardiogram;

               -  complete left bundle branch block;

               -  obligate use of a cardiac pacemaker;

               -  congenital long QT syndrome;

               -  history or presence of ventricular tachyarrhythmia;

               -  presence of unstable atrial fibrillation (ventricular response &gt; 100 bpm).
                  -Patients with stable atrial fibrillation are eligible, provided they do not meet
                  any of the other cardiac exclusion criteria;

               -  clinically significant resting bradycardia (&lt; 50 bpm);

               -  right bundle branch block + left anterior hemiblock (bifascicular block);

               -  angina pectoris = 3 months prior to starting study drug;

               -  acute myocardial infarction (MI) = 3 months prior to starting study drug; or

               -  other clinically significant heart disease (e.g., congestive heart failure (CHF),
                  uncontrolled hypertension, history of labile hypertension, or history of poor
                  compliance with an antihypertensive regimen).

          -  Patients currently receiving treatment with medications known to prolong the QTc
             interval and/or to induce Torsades de Pointes arrhythmia.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>5</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/02/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a clinical research study that is designed to test the safety of CYT997 when given to
      patients with multiple myeloma and to test if CYT997 has any activity against that cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00664378</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Spencer, Assoc Prof.</name>
      <address>Myeloma Research Group, The Alfred Hospital, Melbourne</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>